NYSE: PRGO

PERRIGO Co plc

CIK 0001585364 · SIC 2834 · Pharmaceutical Preparations

Large Revenue $4.3B Assets $7.6B as of Aug 30, 2026

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms… About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.

8-K Filed Aug 5, 2026 · Period ending Aug 5, 2026

Summary not yet generated.

10-Q Filed Aug 5, 2026 · Period ending Jun 27, 2026 Red flag

Perrigo swings to $74.5M net income on non-operating factors as operating income falls 48%

4 material changes detected. Sign up free to read the summary.

Partner

Trade PRGO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Jul 6, 2026 · Period ending Jun 29, 2026

Perrigo reinstates executive severance policy during CEO transition period

3 material changes detected. Sign up free to read the summary.

8-K Filed Jun 30, 2026 · Period ending Jun 30, 2026

Perrigo expands Board to 10, adds consumer products and retail veterans

3 material changes detected. Sign up free to read the summary.

8-K Filed Jun 8, 2026 · Period ending Jun 7, 2026 Red flag

Perrigo CEO resigns immediately after board finds conduct violated company values

4 material changes detected. Sign up free to read the summary.

10-Q Filed May 6, 2026 · Period ending Mar 28, 2026 Red flag

revenue $969.2M, net income -$398.6M. Perrigo posts goodwill impairment, 7% revenue decline as restructuring accelerates

5 material changes detected. Sign up free to read the summary.

8-K Filed May 6, 2026 · Period ending May 6, 2026 Critical

Perrigo reports Q1 2026 earnings with impairment charges, debt loss, and infant formula under review

4 material changes detected. Sign up free to read the summary.

8-K Filed May 5, 2026 · Period ending Apr 30, 2026

Perrigo shareholders approve new 2026 equity compensation plan at annual meeting

3 material changes detected. Sign up free to read the summary.

8-K Filed Apr 30, 2026 · Period ending Apr 30, 2026

Perrigo completes €305.6M sale of Dermacosmetics Business to Karo Healthcare

3 material changes detected. Sign up free to read the summary.

10-K Filed Feb 26, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 5, 2025 · Period ending Sep 27, 2025

Summary not yet generated.

10-Q Filed Aug 6, 2025 · Period ending Jun 28, 2025

Summary not yet generated.

10-Q Filed May 7, 2025 · Period ending Mar 29, 2025

Summary not yet generated.

10-K Filed Feb 28, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed Aug 5, 2026 (period ending Jun 27, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations (Unaudited)

(in millions, except per share amounts)

Description Three months ended June 27, 2026 Three months ended June 28, 2025 Six months ended June 27, 2026 Six months ended June 28, 2025
Net sales 1,022.8 1,056.3 1,992.0 2,100.2
Cost of sales 708.9 693.4 1,352.6 1,345.0
Gross profit 313.9 362.9 639.4 755.2
Operating expenses
Distribution 21.7 23.6 44.3 46.4
Research and development 23.7 22.0 48.4 48.7
Selling 129.5 136.5 259.2 282.7
Administration 100.0 113.0 215.0 225.2
Impairment charges 1.0 1.5 331.8 4.6
Restructuring 14.4 8.7 89.5 38.1
Other operating expense, net 12.2 17.2
Total operating expenses 290.5 317.5 988.3 662.9
Operating income (loss) 23.5 45.4 (348.9) 92.3
Interest expense, net 38.4 39.6 79.3 78.6
Other (income) expense, net (120.5) 2.6 (126.5) 2.2
Loss on extinguishment of debt 0.1 1.4
Income (loss) from continuing operations before income taxes 105.4 3.2 (303.1) 11.5
Income tax expense (benefit) 16.9 3.7 (1.8) 11.9
Income (loss) from continuing operations 88.5 (0.5) (301.3) (0.4)
Loss from discontinued operations, net of tax (14.1) (7.9) (22.8) (14.4)
Net income (loss) 74.5 (8.4) (324.1) (14.8)
Earnings (loss) per share
Basic
Continuing operations 0.64 (0.00) (2.17)
Discontinued operations (0.10) (0.06) (0.16) (0.10)
Basic earnings (loss) per share 0.54 (0.06) (2.33) (0.10)
Diluted
Continuing operations 0.63 (0.00) (2.17)
Discontinued operations (0.10) (0.06) (0.16) (0.10)
Diluted earnings (loss) per share 0.53 (0.06) (2.33) (0.10)
Weighted-average shares outstanding
Basic 139.1 138.2 138.9 138.0
Diluted 139.6 138.2 138.9 138.0

Condensed Consolidated Balance Sheets (Unaudited)

(in millions, except per share amounts)

Description June 27, 2026 December 31, 2025
Assets
Cash and cash equivalents 399.7 531.6
Accounts receivable, net of allowance for credit losses of $3.9 and $6.5, respectively 709.9 612.8
Inventories 1,064.5 1,149.0
Prepaid expenses and other current assets 277.7 231.4
Current assets held for sale 272.6
Total current assets 2,451.7 2,797.4
Property, plant and equipment, net 849.0 898.7
Operating lease assets 156.0 167.8
Goodwill and indefinite-lived intangible assets 1,697.6 2,054.7
Definite-lived intangible assets, net 2,190.2 2,351.5
Deferred income taxes 6.3 3.3
Other non-current assets 258.6 261.8
Total non-current assets 5,157.7 5,737.8
Total assets 7,609.5 8,535.2
Liabilities and Shareholders’ Equity
Liabilities
Accounts payable 400.4 474.5
Payroll and related taxes 153.2 112.2
Accrued customer programs 109.4 111.4
Other accrued liabilities 265.4 216.1
Accrued derivative liabilities 86.2 14.5
Accrued income taxes 28.8 20.8
Current indebtedness 11.4 36.6
Current liabilities held for sale 26.8
Total current liabilities 1,054.8 1,012.9
Non-current liabilities
Long-term debt, less current portion 3,283.4 3,603.6
Deferred income taxes 146.7 168.9
Other non-current liabilities 608.8 814.3
Total non-current liabilities 4,038.9 4,586.8
Total liabilities 5,093.7 5,599.7
Contingencies - Refer to Note 16
Shareholders’ equity
Controlling interests:
Preferred shares, $0.0001 par value per share, 10 shares authorized
Ordinary shares, €0.001 par value per share, 10,000 shares authorized 6,540.5 6,608.2
Accumulated other comprehensive income (loss) (22.8) 4.8
Retained earnings (accumulated deficit) (4,001.9) (3,677.5)
Total shareholders’ equity 2,515.8 2,935.5
Total liabilities and shareholders' equity 7,609.5 8,535.2
Supplemental Disclosures of Balance Sheet Information
Preferred shares, issued and outstanding
Ordinary shares, issued and outstanding 138.7 137.6

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in millions)

Description Six months ended June 27, 2026 Six months ended June 28, 2025
Cash Flows From (For) Operating Activities
Net income (loss) (324.1) (14.8)
Adjustments to derive cash flows:
Depreciation and amortization 179.1 166.2
Restructuring charges 84.9 35.0
Share-based compensation 21.2 28.4
Impairment charges 331.8 4.6
Amortization of debt discount 4.1 4.4
Deferred income taxes (19.3) 9.6
(Gain) loss on sale of business (129.5) 1.6
Amortization on hedging instruments (10.3) (12.6)
Other non-cash adjustments, net (8.7) 1.2
Subtotal 129.3 223.6
Increase (decrease) in cash due to:
Inventories 74.2 (97.4)
Accrued income taxes (13.4) (54.5)
Payroll and related taxes (45.0) (23.6)
Accounts payable (66.8) (19.9)
Accrued customer programs 0.5 (0.6)
Other accrued liabilities 44.4 (29.3)
Accounts receivable (102.3) (5.9)
Other long term liabilities 2.6 2.4
Prepaid expenses and other current assets (54.6) 16.6
Subtotal (160.3) (212.2)
Net cash (for) from operating activities (31.0) 11.4
Cash Flows From (For) Investing Activities
Net proceeds from sale of businesses 362.9 14.4
Asset acquisitions, net (1.5)
Additions to property, plant and equipment (28.1) (44.7)
Other investing, net 2.2 2.3
Net cash from (for) investing activities 337.0 (29.5)
Cash Flows From (For) Financing Activities
Payments on long-term debt (759.3) (17.6)
Cash dividends (80.1) (79.5)
Borrowings of revolving credit agreements and other financing, net 427.6
Payments for debt issuance costs (5.5)
Shares used to settle taxes (7.0) (17.7)
Other financing, net (9.9) (1.0)
Net cash for financing activities (434.2) (115.8)
Effect of exchange rate changes on cash and cash equivalents (6.1) 29.3
Net decrease in cash and cash equivalents (134.2) (104.6)
Cash and cash equivalents of continuing operations, beginning of period 531.6 558.8
Cash and cash equivalents held for sale, beginning of period 2.3
Less cash and cash equivalents held for sale, end of period
Cash and cash equivalents of continuing operations, end of period 399.7 454.2

Amounts as printed on the EDGAR/iXBRL face — (in millions, except per share amounts); (in millions). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

View AI report for this filing

About PERRIGO Co plc

Source: Item 1 (Business) from the 10-K filed February 26, 2026. Description as filed by the company with the SEC.

ITEM 1. BUSINESS

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

WHO WE ARE

Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All".

Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for:

•Access: Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness.

•Value: Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions.

•Reliability: Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers.

Read full description ↓

Perrigo provides access to trusted self-care solutions that can be used without the need to visit a health practitioner for a prescription. Guided by our vision and purpose, our strategic goal is to create sustainable and value accretive growth by 1) delivering consumer preferred brands and innovation, 2) driving category growth with our customers, 3) powering our business with our world-class, quality assured supply chain, including a focus on sustainability with meaningful goals to reduce greenhouse gas emissions, water, and waste, in addition to increasing the recyclability of our packaging, and 4) evolving our global organization to one cohesive operating model. Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.

Perrigo's broad offerings are well diversified across several major product categories as well as across geographies, primarily in North America and Europe, with no one product representing more than 5% of total revenue. In North America, Perrigo is the leading store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill® and Mederma®. In Europe, our portfolio consists primarily of brands, including Compeed®, ellaOne®, Solpadeine®, Jungle Formula®, and ACO®.

Two key initiatives have been fundamental in advancing our self-care strategy — our Supply Chain Reinvention Program, a global supply chain efficiency program, and Project Energize, a global investment and efficiency program. In addition, we continue to invest in other initiatives, including innovation, information systems and tools, and our people to drive consistent and sustainable results.

Perrigo’s unique complementary businesses enable each individually to play a specific reinforcing role, where 1) store brands generate cash for investments into the Company’s key higher margin, higher growth brands, 2) branding and innovation capabilities deliver both brand and store brand demand generation designed to lead to stronger customer partnerships, 3) consumer-led innovation scaled across brands, store brands and geographies, and 4) leveraging global supply chain scale of more molecules at more price points to more consumers driving household penetration.

The Company’s plan to drive cash flow and total shareholder return is anchored behind its ‘Three-S’ plan – ‘Stabilizing’ Consumer Self-Care Americas store brand and infant formula businesses; ‘Streamlining’ the global portfolio, enterprise operating model and Consumer Self-Care International business; and ‘Strengthening’ what is working by prioritizing and increasing investments behind key brands. Further 2025 highlights can be found in